EUVIMEDEUVIMED entdecken
Crossref

Development and Validation for the Quantification of Genotoxic Impurity in Mirabegron Drug Substance by LCMS

Haresh B Patel iD, Rohit H Dave, Sandip Vadariya, Hitin Hirpara

Biomedical Chromatography · 2025

DOI: 10.1002/bmc.70150 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Haresh B Patel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Analytical R&D, Cohance Lifesciences Ltd, Ankleshwar, Gujarat, India. Hauptthemen laut MEDLINE: Acetanilides, Thiazoles, Tandem Mass Spectrometry, Drug Contamination. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mirabegron drug substance was shown to have potential genotoxic impurity (PGI); hence, it needs to develop the method for the determination of the 2‐(2‐Nitrophenyl) ethylamine hydrochloride (4‐NPE RC‐2) PGI at a 30‐ppm limit considering the maximum daily dose of 50 mg/day and a 1.5 mg per day TTC limit as per ICH M7 guideline. A simple high‐performance liquid chromatography (HPLC) method can be used due to the chromophore nature of the impurity, but due to sample matrix interference on the HPLC method, a selective and specific method was developed using liquid chromatography‐mass spectrometry (LC–MS/MS) method. Using an Inertsil ODS 3‐V column, gradient elution mode, 0.8 mL per min flow rate, 0.2% formic acid aqueous solution as mobile phase A, and acetonitrile solvent as mobile phase B was used for better chromatographic separation. Triple quadrupole mass detection with electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode was used for determination and quantification. For this PGI, the procedure was thoroughly verified with good linearity across the mirabegron test concentration range of 9–45 ppm. Linearity was observed with an exceeding 0.990 correlation coefficient and found accuracy in terms of recovery between 100.0% and 103.0% with below 5.0% relative standard deviation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcetanilidesThiazolesTandem Mass SpectrometryDrug ContaminationMutagensLimit of DetectionReproducibility of ResultsLinear ModelsChromatography, High Pressure LiquidChromatography, Liquid

Stichwörter der Autor:innen

LCMS analysisgenotoxic impuritiesmethod developmentmethod validationmirabegron

Substanzen

mirabegronAcetanilidesThiazolesMutagens

Autor:innen und Institutionen

  • Analytical R&D, Cohance Lifesciences Ltd, Ankleshwar, Gujarat, India.
  • Department of Industrial Chemistry, Institute of Science & Technology for Advanced Studies & Research, Anand, Gujarat, India.
  • Chemical Research Synthesis R&D, Cohance Lifesciences Ltd, Ankleshwar, Gujarat, India.

ORCID-Profile: Haresh B Patel

Zitieren

APA

Patel, H. B., Dave, R. H., Vadariya, S., & Hirpara, H. (2025). Development and Validation for the Quantification of Genotoxic Impurity in Mirabegron Drug Substance by LCMS. Biomedical Chromatography. https://doi.org/10.1002/bmc.70150

Vancouver

Patel HB, Dave RH, Vadariya S, Hirpara H. Development and Validation for the Quantification of Genotoxic Impurity in Mirabegron Drug Substance by LCMS. Biomedical Chromatography. 2025. doi:10.1002/bmc.70150

BibTeX
@article{Patel2025,
  author = {Patel, Haresh B and Dave, Rohit H and Vadariya, Sandip and Hirpara, Hitin},
  title = {Development and Validation for the Quantification of Genotoxic Impurity in Mirabegron Drug Substance by LCMS},
  journal = {Biomedical Chromatography},
  year = {2025},
  doi = {10.1002/bmc.70150}
}
Kostenlos starten →